Protalix BioTherapeutics Inc. (NYSE:PLX) was the target of a large increase in short interest in September. As of September 30th, there was short interest totalling 742,145 shares, an increase of 4.2% from the September 15th total of 712,565 shares. Based on an average daily trading volume, of 58,421 shares, the days-to-cover ratio is presently 12.7 days. Currently, 0.8% of the company’s stock are short sold.

Shares of Protalix BioTherapeutics (NYSE:PLX) opened at 0.5081 on Friday. The company has a 50 day moving average price of $0.58 and a 200 day moving average price of $0.70. Protalix BioTherapeutics has a 52 week low of $0.49 and a 52 week high of $1.25. The company has a market cap of $50.69 million and a PE ratio of 1.0042.

Protalix BioTherapeutics (NYSE:PLX) last issued its earnings results on Monday, August 8th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.08) by $0.03. The business earned $1.77 million during the quarter, compared to analysts’ expectations of $1.34 million. During the same quarter in the prior year, the business posted ($0.05) EPS. On average, equities analysts expect that Protalix BioTherapeutics will post ($0.41) earnings per share for the current year.

Several brokerages recently commented on PLX. Zacks Investment Research cut Protalix BioTherapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, August 24th. Rodman & Renshaw reissued a “buy” rating on shares of Protalix BioTherapeutics in a research note on Monday, July 11th. Finally, Jefferies Group lowered their price target on Protalix BioTherapeutics from $1.75 to $0.80 and set a “buy” rating for the company in a research note on Tuesday, September 6th.

5 Day Chart for NYSE:PLX

Receive News & Stock Ratings for Protalix BioTherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protalix BioTherapeutics Inc. and related stocks with our FREE daily email newsletter.